Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Amplyx

Amplyx
2006 FOUNDED
PRIVATE STATUS
11-20 EMPLOYEES
Series C LATEST DEAL TYPE
$118M LATEST DEAL AMOUNT
21 INVESTORS
Description

Developer of broad-spectrum antifungal agents designed to treat invasive fungal infections. The company's small-molecule therapy, APX001, uses both intravenous and oral formulations to address the need for treatment in both the hospital setting and continued convenient treatment after discharge from hospital, enabling patients undergoing chemotherapy and other immunosuppressive treatments, with compromised immune systems, to get proper treatment for life-threatening invasive fungal infections due to candida, aspergillus and rare molds.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Primary Office
  • 12730 High Bluff Drive
  • Suite 160
  • San Diego, CA 92130
  • United States

+1 (858) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Amplyx’s full profile, request a free trial.

Amplyx Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC (Series C) 09-Jan-2020 $118M 00000 Completed Generating Revenue
8. Accelerator/Incubator 28-Feb-2017 000.00 Completed Generating Revenue
7. Later Stage VC (Series B) 09-Feb-2016 000.00 000.00 0000 Completed Generating Revenue
6. Grant 00.000 00.000 Completed Generating Revenue
5. Grant 01-Jul-2014 00.000 00.000 Completed Generating Revenue
4. Grant 01-Jul-2013 00.000 00.000 Completed Generating Revenue
3. Grant 01-Aug-2012 00.000 00.000 Completed Generating Revenue
2. Grant 01-Jul-2011 $700K $2.23M Completed Startup
1. Early Stage VC (Series A) 01-Jan-2011 $2.23M $2.23M 000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Amplyx Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series C 000,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B 000,000,000 00.000000 00 00.00 00.00 00 00.00 00.00
Series A 8,243,027 $0.001000 8% $0.27 $0.27 1x $0.27 2.31%
To view this company’s complete Cap Table, request access »

Amplyx Competitors (32)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Samumed Private Equity-Backed San Diego, CA 000 00000 0000000 0000 00000
000 Venture Capital-Backed Manchester, United Kingdom 00 000.00 000000 - 000 000.00
000000 00000 Private Equity-Backed Durham, NC 00 00000 000000000000 00000
00000 000000 Venture Capital-Backed New York, NY 0000 0000000000 0 0000
000000 00000000000 Private Equity-Backed Copenhagen, Denmark 0000 000000000000
To view this company’s complete list of competitors, request access »

Amplyx Investors (21)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Arix Bioscience Venture Capital Minority 000 0000 000000 0
Generation Ventures (Palo Alto) Venture Capital Minority 000 0000 000000 0
Lundbeckfonden Limited Partner Minority 000 0000 000000 0
Lundbeckfond Ventures Corporate Venture Capital Minority 000 0000 000000 0
Lymo Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 21 investors. Get the full list »

Amplyx Executive Team (12)

Name Title Board
Seat
Contact
Info
Ciara Kennedy Ph.D President, Chief Executive Officer and Board Member
Alan Fuhrman Chief Financial Officer
Karen Shaw Ph.D Chief Scientific Officer
Susan Dubé Vice President of Business Development and Administration
Pamela Wedel Vice President of Clinical Operations

4 Former Executives

You’re viewing 5 of 12 executives. Get the full list »

Amplyx Board Members (13)

Name Representing Role Since Contact
Info
Anand Mehra MD Sofinnova Investments Board Member 000 0000
Edward Mathers Self Board Member 000 0000
Elaine Heron Ph.D Amplyx Board Member 000 0000
Johan Kördel Ph.D Lundbeckfonden Board Member 000 0000
Mark Chin Arix Bioscience Board Observer 000 0000

5 Former Board Members

You’re viewing 5 of 13 board members. Get the full list »